Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The apolipoprotein E type 4 allele ( APOE -ε4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE -ε4 alleles in 42 families with late onset AD. Thus APOE -ε4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE -ε4 was virtually sufficient to cause AD by age 80.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
91 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationMiller, R. G. (1981) · Cited by 3,336
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citationNamba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Genetic Linkage Evidence for a Familial Alzheimer's Disease Locus on Chromosome 14
Schellenberg, G. D., Bird, T. D., Wijsman, E. M., Orr, H. T., Anderson, L., Nemens, E., White, J. A., Bonnycastle, L., Weber, J. L., Alonso, M. E., et al. (1992) · Science · doi:10.1126/science.1411576 · Cited by 946
Research works printed but not linked: 3
- SAS/STAT User's Guide Release 6.03 Edition (1988).
- SAS User's Guide: Statistics Version 5 Edition (1985).
- 10.1073/pnas.90.5.1977 · DOI · Paper page
Cited by
Items 401–500 of 1,689
Harris, F. M., Brecht, W. J., Xu, Q., Tesseur, I., Kekonius, L., Wyss-Coray, T., Fish, J. D., Masliah, E., Hopkins, P. C., Scearce-Levie, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1434398100 · Cited by 342
Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases
Vance, J. E. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.010124 · Cited by 342
“Importantly, inheritance of the APOE4 allele is the strongest known genetic risk factor for the development of late-onset AD (Corder et al., 1993).”
BackgroundPsychiatric genetics: search for phenotypes
Leboyer, M., Leboyer, M., Bellivier, F., Jouvent, R., Nosten-Bertrand, M., Mallet, J., & Pauls, D. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01187-9 · Cited by 335
Role of Oxidative Stress and Antioxidants in Neurodegenerative Diseases
Rao, A. V., & Balachandran, B. (2002) · Nutritional Neuroscience · doi:10.1080/1028415021000033767 · Cited by 336
“The apoE gene is inherited as one of three alleles, 12, 13 and 14, with the 14 allele conferring increased risk of developing AD in older adults in a “gene-dose” manner (Corder et al., 1993).”
BackgroundUsefulness of MRI measures of entorhinal cortex versus hippocampus in AD
Xu, Y., Jack, C. R., O’Brien, P. C., Kokmen, E., Smith, G. E., Ivnik, R. J., Boeve, B. F., Tangalos, R. G., & Petersen, R. C. (2000) · Neurology · doi:10.1212/wnl.54.9.1760 · Cited by 336
Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau
Hohman, T. J., Dumitrescu, L., Barnes, L. L., Thambisetty, M., Beecham, G., Kunkle, B., Gifford, K. A., Bush, W. S., Chibnik, L. B., Mukherjee, S., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0821 · Cited by 340
“Mild cognitive impairment 11 (10) 2 (1) 9 (17) 12 (13) 358 (54) 255 (47) 46 (45) 26 (51)”
Self-citationMolecular Basis of Familial and Sporadic Alzheimer's Disease
Dorszewska, J., Prendecki, M., Oczkowska, A., Dezor, M., & Kozubski, W. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160314150501 · Cited by 329
Cholesterol: its regulation and role in central nervous system disorders
Orth, M., & Bellosta, S. (2012) · Cholesterol · doi:10.1155/2012/292598 · Cited by 339
“Epidemiological studies highlighted the ε4 allele of Apoe as the most common risk factor for late-onset Alzheimer’s disease [186], and in vitro studies showed a colocalization of apoE with amyloid plaques [187] and a positive correlation between plaque density and number of ε4 alleles in Alzheimer’ patients at autopsy…”
BackgroundApolipoprotein E Polymorphism and Alzheimer Disease: The Indo-US Cross-National Dementia Study
Ganguli, M., Chandra, V., Kamboh, M. I., Johnston, J. M., Dodge, H. H., Thelma, B. K., Juyal, R. C., Pandav, R., Belle, S. H., & DeKosky, S. T. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.824 · Cited by 337
Neuronal membrane cholesterol loss enhances amyloid peptide generation
Abad-Rodriguez, J., Ledesma, M. D., Craessaerts, K., Perga, S., Medina, M., Delacourte, A., Dingwall, C., De Strooper, B., & Dotti, C. G. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200404149 · Cited by 333
“More than a decade ago Roses and colleagues (Corder et al., 1993) demonstrated the existence of a genetic link between the risk of AD and the 4 allele of apolipoprotein E, a protein involved in cholesterol homeostasis (Myers and Goate, 2001).”
BackgroundBu�e, L., Hof, P. R., Bouras, C., Delacourte, A., Perl, D. P., Morrison, J. H., & Fillit, H. M. (1994) · Acta Neuropathologica · doi:10.1007/bf00294173 · Cited by 334
“Finally, recent studies have demonstrated that apolipoprotein E4, a major risk factor for vascular disease [9], is also a risk factor for AD [ 6 ].”
APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia
Sienski, G., Narayan, P., Bonner, J. M., Kory, N., Boland, S., Arczewska, A. A., Ralvenius, W. T., Akay, L., Lockshin, E., He, L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz4564 · Cited by 336
Immune Signaling in Neurodegeneration
Hammond, T. R., Marsh, S. E., & Stevens, B. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.016 · Cited by 336
“There is a significant association between the age of onset in sporadic AD and APOE, plus other immune-enriched loci like CR1, PICALM, and BIN1 (Corder et al., 1993; Naj et al., 2014).”
BackgroundEvidence that Aβ42 is the real culprit in alzheimer's disease
Younkin, S. G. (1995) · Annals of Neurology · doi:10.1002/ana.410370303 · Cited by 333
Human apolipoprotein E: the Alzheimer's disease connection
Weisgraber, K. H., & Mahley, R. W. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.13.8940294 · Cited by 331
“apoE, apoE4, was associated with Alzheimer’s disease (AD) (6, 7).”
BackgroundEvans, K. C., Berger, E. P., Cho, C. G., Weisgraber, K. H., & Lansbury, P. T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.3.763 · Cited by 333
Ruchoux, M. M., Guerouaou, D., Vandenhaute, B., Pruvo, J.-P., Vermersch, P., & Leys, D. (1995) · Acta Neuropathologica · doi:10.1007/bf00571504 · Cited by 329
Cholinergic dysfunction in diseases with Lewy bodies
Tiraboschi, P., Hansen, L. A., Alford, M., Sabbagh, M. N., Schoos, B., Masliah, E., Thal, L. J., & Corey-Bloom, J. (2000) · Neurology · doi:10.1212/wnl.54.2.407 · Cited by 328
APOE ε4: The most prevalent yet understudied risk factor for Alzheimer's disease
Michaelson, D. M. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.015 · Cited by 331
“About 60% of the AD patients in the Caucasian population are APOE ε4 carriers and this reduces the age of onset of the disease in a gene dose-dependent manner by as much as 7 to 9 years per allele copy [2].”
BackgroundBrioni, J. D., Esbenshade, T. A., Garrison, T. R., Bitner, S. R., & Cowart, M. D. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166876 · Cited by 203
Neuroinflammation in Alzheimer’s Disease
Onyango, I. G., Jauregui, G. V., Čarná, M., Bennett, J. P., & Stokin, G. B. (2021) · Biomedicines · doi:10.3390/biomedicines9050524 · Cited by 330
“LOAD, however, comprises most AD cases (>95%) where the greatest risk factor is advanced age [51], while the common genetic risk factor is an allelic variation in apolipoprotein E (Apo E) [52].”
BackgroundAdult Hippocampal Neurogenesis in Aging and Alzheimer's Disease
Babcock, K. R., Page, J. S., Fallon, J. R., & Webb, A. E. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.01.019 · Cited by 313
Alzheimer’s disease: analyzing the missing heritability
Ridge, P. G., Mukherjee, S., Crane, P. K., Kauwe, J. S. K., & Alzheimer’s Disease Genetics Consortium (2013) · PLoS ONE · doi:10.1371/journal.pone.0079771 · Cited by 328
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
the Synaptic Health Endpoints Working Group, Colom-Cadena, M., Spires-Jones, T., Zetterberg, H., Blennow, K., Caggiano, A., DeKosky, S. T., Fillit, H., Harrison, J. E., Schneider, L. S., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00588-4 · Cited by 328
Sorting through the Cell Biology of Alzheimer's Disease: Intracellular Pathways to Pathogenesis
Small, S. A., & Gandy, S. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.001 · Cited by 324
de Wolf, F., Ghanbari, M., Licher, S., McRae-McKee, K., Gras, L., Weverling, G. J., Wermeling, P., Sedaghat, S., Ikram, M. K., Waziry, R., et al. (2020) · Brain · doi:10.1093/brain/awaa054 · Cited by 324
“7%) were APOE e4 carriers (homozygous plus heterozygous) (Corder et al., 1993).”
Apolipoprotein E4 effects in Alzheimer’s disease are mediated by synaptotoxic oligomeric amyloid-β
Koffie, R. M., Hashimoto, T., Tai, H.-C., Kay, K. R., Serrano-Pozo, A., Joyner, D., Hou, S., Kopeikina, K. J., Frosch, M. P., Lee, V. M., et al. (2012) · Brain · doi:10.1093/brain/aws127 · Cited by 327
Andrews-Zwilling, Y., Bien-Ly, N., Xu, Q., Li, G., Bernardo, A., Yoon, S. Y., Zwilling, D., Yan, T. X., Chen, L., & Huang, Y. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4040-10.2010 · Cited by 326
“Apolipoprotein E4 (apoE4), the major known genetic risk factor for Alzheimer’s disease (Corder et al., 1993; Strittmatter et al., 1993), colocalizes with amyloid plaques and neurofibrillary tangles (Namba et al., 1991; Wisniewski and Frangione, 1992; Strittmatter et al., 1993).”
BackgroundInfluentialCausative and susceptibility genes for Alzheimer’s disease: a review
Rocchi, A., Pellegrini, S., Siciliano, G., & Murri, L. (2003) · Brain Research Bulletin · doi:10.1016/s0361-9230(03)00067-4 · Cited by 316
Impact of apoE genotype on oxidative stress, inflammation and disease risk
Jofre‐Monseny, L., Minihane, A., & Rimbach, G. (2008) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700322 · Cited by 318
“Alzheimer's disease [101, 102] Traumatic brain injury outcome [26, 27] Postoperative cognitive dysfunction [28, 29] HIV-associated dementia [31] Cardiovascular disease [103] Left ventricular failure in b-thalassemia [33] Psoriasis [32] Hepatitis C [38] Diarrhoea in children [36, 37] Age-related macular degeneration [3…”
The amyloid cascade hypothesis: an updated critical review
Kepp, K. P., Robakis, N. K., Høilund-Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 284
Deletion of Abca1 Increases Aβ Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease
Wahrle, S. E., Jiang, H., Parsadanian, M., Hartman, R. E., Bales, K. R., Paul, S. M., & Holtzman, D. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508780200 · Cited by 325
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores
de Rojas, I., Moreno-Grau, S., Tesi, N., Grenier-Boley, B., Andrade, V., Jansen, I. E., Pedersen, N. L., Stringa, N., Zettergren, A., Hernández, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22491-8 · Cited by 324
The Endosomal-Lysosomal System of Neurons in Alzheimer's Disease Pathogenesis: A Review
Nixon, R. A., Cataldo, A. M., & Mathews, P. M. (2000) · Neurochemical Research · doi:10.1023/a:1007675508413 · Cited by 318
“strong risk factor for late-onset AD (16).”
The neuroprotective effects of caffeine in neurodegenerative diseases
Kolahdouzan, M., & Hamadeh, M. J. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12684 · Cited by 302
Evolution in Health and Disease
(2007) · doi:10.1093/acprof:oso/9780199207466.001.0001 · Cited by 320
Accelerating Cortical Thinning: Unique to Dementia or Universal in Aging?
Fjell, A. M., Westlye, L. T., Grydeland, H., Amlien, I., Espeseth, T., Reinvang, I., Raz, N., Dale, A. M., Walhovd, K. B., & Initiative, F. T. A. D. N. (2014) · Cerebral Cortex · doi:10.1093/cercor/bhs379 · Cited by 305
Dong, L. M., Wilson, C., Wardell, M. R., Simmons, T., Mahley, R. W., Weisgraber, K. H., & Agard, D. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31797-0 · Cited by 320
Apolipoprotein E: From lipid transport to neurobiology
Hauser, P. S., Narayanaswami, V., & Ryan, R. O. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.09.001 · Cited by 320
“factor for development of the disease, including early and late onset non-familial [48,163] and sporadic forms [164–166].”
BackgroundChang, S., Ma, T. R., Miranda, R. D., Balestra, M. E., Mahley, R. W., & Huang, Y. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508254102 · Cited by 319
Arendt, T., Schindler, C., Brückner, M. K., Eschrich, K., Bigl, V., Zedlick, D., & Marcova, L. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-02-00516.1997 · Cited by 319
“This earlier age of onset is a consistent finding associated with apoE e4/4 (Corder et al., 1993; Soininen, 1995).”
BackgroundLewczuk, P., Riederer, P., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramirez, A., Parnetti, L., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 307
“For more than 20 years, the only known genetic susceptibility factor for LOAD was the APOE gene encoding the apoliprotein E (ApoE) (Corder et al. 1993; Strittmatter et al. 1993).”
BackgroundHuman Apolipoprotein E4 Domain Interaction
Dong, L.-M., & Weisgraber, K. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.32.19053 · Cited by 318
Mouse models of Alzheimer's disease
Hall, A. M., & Roberson, E. D. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.11.017 · Cited by 317
Loss of apolipoprotein E receptor LR11 in Alzheimer disease
Scherzer, C. R., Offe, K., Gearing, M., Rees, H. D., Fang, G., Heilman, C. J., Schaller, C., Bujo, H., Levey, A. I., & Lah, J. J. (2004) · Archives of Neurology · doi:10.1001/archneur.61.8.1200 · Cited by 316
“This exploratory study suggests that gene expression analysis of widely available lymphoblasts derived from patients with AD holds promise as a primary screen for candidate genes associated with AD.”
BackgroundInfluentialApoE Cascade Hypothesis in the pathogenesis of Alzheimer’s disease and related dementias
Martens, Y. A., Zhao, N., Liu, C.-C., Kanekiyo, T., Yang, A. J., Goate, A. M., Holtzman, D. M., & Bu, G. (2022) · Neuron · doi:10.1016/j.neuron.2022.03.004 · Cited by 316
Neuroinflammation: Modulation by flavonoids and mechanisms of action
Spencer, J. P. E., Vafeiadou, K., Williams, R. J., & Vauzour, D. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.10.016 · Cited by 315
MULLER, U. (1994) · Cell · doi:10.1016/0092-8674(94)90066-3 · Cited by 306
Goldstein, D. B., Tate, S. K., & Sisodiya, S. M. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1229 · Cited by 312
“gov/htbin-post/Omim/dispmim?104300">Alzheimer disease”
Microglia, Lifestyle Stress, and Neurodegeneration
Madore, C., Yin, Z., Leibowitz, J., & Butovsky, O. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.003 · Cited by 311
“Genetic variants of TREM2, most strongly R47H, also result in an increased risk of developing LOAD and other neurodegenerative diseases (Guerreiro et al., 2013; Ulrich and Holtzman, 2016).”
BackgroundInfluentialThe neuroimmune axis of Alzheimer’s disease
Jorfi, M., Maaser-Hecker, A., & Tanzi, R. E. (2023) · Genome Medicine · doi:10.1186/s13073-023-01155-w · Cited by 292
“A viral-mediated overexpression of APOE ε2 in amyloid mouse model brains led to a reduction of the Aβ burden, which might be attributed to an increased Aβ clearance in APOE ε2 expressing animals [321].”
BackgroundInfluentialBellosta, S., Nathan, B. P., Orth, M., Dong, L.-M., Mahley, R. W., & Pitas, R. E. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.27063 · Cited by 313
Age at Onset in Two Common Neurodegenerative Diseases Is Genetically Controlled
Li, Y.-J., Scott, W. K., Hedges, D. J., Zhang, F., Gaskell, P. C., Nance, M. A., Watts, R. L., Hubble, J. P., Koller, W. C., Pahwa, R., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/339815 · Cited by 312
“41 amination of APOE, a known modulator of AAO in AD (Corder et al. 1993), generated a LOD score of 3.”
BackgroundInfluentialSelf-citationBuckingham, S. D., Jones, A. K., Brown, L. A., & Sattelle, D. B. (2009) · Pharmacological Reviews · doi:10.1124/pr.108.000562 · Cited by 308
“APOE- 4 has been found to be a major risk factor for late familial or sporadic AD, with a strong gene-dosage effect such that the number of APOE- 4 alleles correlated positively with the risk of developing AD and the age of onset (Corder et al., 1993).”
Genes associated with Alzheimer's disease: an overview and current status
Giri, M., Lü, Y., & Zhang, M. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s105769 · Cited by 311
Liang, W. S., Dunckley, T., Beach, T. G., Grover, A., Mastroeni, D., Ramsey, K., Caselli, R. J., Kukull, W. A., McKeel, D., Morris, J. C., et al. (2008) · Physiological Genomics · doi:10.1152/physiolgenomics.00242.2007 · Cited by 309
Self-citationApolipoprotein E: from atherosclerosis to Alzheimerʼs disease and beyond
Mahley, R. W., & Huang, Y. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199906000-00003 · Cited by 308
Hariri, A. R., & Weinberger, D. R. (2003) · British Medical Bulletin · doi:10.1093/bmb/65.1.259 · Cited by 292
Modulation of memory by insulin and glucose: Neuropsychological observations in Alzheimer’s disease
Watson, G. S., & Craft, S. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.048 · Cited by 307
Sex differences in cognitive impairment in Alzheimer’s disease
Laws, K. R., Irvine, K., & Gale, T. M. (2016) · World Journal of Psychiatry · doi:10.5498/wjp.v6.i1.54 · Cited by 307
Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats
Nieweg, K., Schaller, H., & Pfrieger, F. W. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05917.x · Cited by 307
Warfarin-associated hemorrhage and cerebral amyloid angiopathy: A genetic and pathologic study
Rosand, J., Hylek, E. M., O’Donnell, H. C., & Greenberg, S. M. (2000) · Neurology · doi:10.1212/wnl.55.7.947 · Cited by 305
Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism
Song, W. M., Joshita, S., Zhou, Y., Ulland, T. K., Gilfillan, S., & Colonna, M. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171529 · Cited by 305
“, 2013) stands out as having an effect size similar to the well-characterized ApoE ε4 allele (Corder et al., 1993; Rebeck et al., 1993).”
BackgroundSutphen, C. L., Jasielec, M. S., Shah, A. R., Macy, E. M., Xiong, C., Vlassenko, A. G., Benzinger, T. L. S., Stoops, E. E. J., Vanderstichele, H. M. J., Brix, B., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1285 · Cited by 295
Deciphering the Genetic Basis of Alzheimer's Disease
Selkoe, D. J., & Podlisny, M. B. (2002) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.3.022502.103022 · Cited by 294
“Inheritance of one or two ε4 alleles heightens the likelihood of developing AD and results in an earlier mean age of onset than occurs in subjects harboring only ε2 and ε3 alleles (22).”
BackgroundLiu, R.-Y., Zhou, J.-N., van Heerikhuize, J., Hofman, M. A., & Swaab, D. F. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.1.5394 · Cited by 304
The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E
Bailey, C. C., DeVaux, L. B., & Farzan, M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.677286 · Cited by 303
“The identification of ApoE as a TREM2 ligand is especially interesting due to the well established role of the ApoE genotype as a determinant of Alzheimer disease risk (34, 35).”
BackgroundHerpes Simplex Virus-1 in the Brain: The Dark Side of a Sneaky Infection
Marcocci, M. E., Napoletani, G., Protto, V., Kolesova, O., Piacentini, R., Li Puma, D. D., Lomonte, P., Grassi, C., Palamara, A. T., & De Chiara, G. (2020) · Trends in Microbiology · doi:10.1016/j.tim.2020.03.003 · Cited by 303
“Subsequent postmortem studies of small patient cohorts detected latent HSV-l in brain samples from both AD patients and healthy elderly controls [68], and showed a correlation in AD patients between HSV-1 infection and the ε4 allele of apolipoprotein E (ApoE-ε4) [69], a known risk factor for AD [70] that is associated…”
BackgroundMichaelis, K., Hoffmann, M. M., Dreis, S., Herbert, E., Alyautdin, R. N., Michaelis, M., Kreuter, J., & Langer, K. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097139 · Cited by 303
“Apolipoprotein E3 is the most frequent one, followed by apolipoprotein E4 and apolipoprotein E2 in Caucasian populations (Davignon et al., 1988; Corder et al., 1993; Weisgraber, 1994).”
BackgroundAltered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2
Ulrich, J. D., Finn, M. B., Wang, Y., Shen, A., Mahan, T. E., Jiang, H., Stewart, F. R., Piccio, L., Colonna, M., & Holtzman, D. M. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-20 · Cited by 302
“To date the two strongest identified LOAD genetic risk factors are the well-studied apolipoprotein ε4 (APOE4) allele and several recently identified variants in the triggering receptor expressed on myeloid cells-2 (TREM2) gene [2-4].”
BackgroundThe role of TNF and its receptors in Alzheimer's disease
Perry, R. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00291-3 · Cited by 297
“The other AD gene, apolipoprotein E (APOE) 4 allele, especially in its homozygous form, is a major risk factor for late-onset AD [41,135,139] and may act by lowering the age at onset of AD [14,33,99].”
BackgroundChen, X.-Q., & Mobley, W. C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00659 · Cited by 289
Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol
Wang, H., Kulas, J. A., Wang, C., Holtzman, D. M., Ferris, H. A., & Hansen, S. B. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102191118 · Cited by 301
“Interestingly, apoE, specifically the e4 subtype (apoE4), is the strongest genetic risk factor associated with sporadic AD (28, 29).”
BackgroundMouse models of experimental atherosclerosis.
Jawień, J., Nastałek, P., & Korbut, R. (2004) · PubMed · Cited by 404
Exercise counteracts declining hippocampal function in aging and Alzheimer's disease
Intlekofer, K. A., & Cotman, C. W. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.06.011 · Cited by 286
“There are three major Apolipoprotein E (APOE) alleles in humans, ε2, ε3 and ε4, but only ε4 is associated with increased risk for AD (Corder et al., 1993) and greater Aβ deposition (Morris et al., 2010).”
BackgroundAlzheimer disease, the two-hit hypothesis: An update
Zhu, X., Lee, H.-G., Perry, G., & Smith, M. A. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.10.014 · Cited by 292
“Several independent hypotheses have been proposed to link the pathological lesions and neuronal cytopathology with, among others, apolipoprotein E genotype [2,3]; hyperphosphorylation of cytoskeletal proteins [4], oxidative stress [5], abnormal cell cycle re-entry [6,7], inflammation [8] and amyloid-β (Aβ) metabolism…”
BackgroundGenetic studies of accelerometer-based sleep measures yield new insights into human sleep behaviour
Jones, S. E., van Hees, V. T., Mazzotti, D. R., Marques-Vidal, P., Sabia, S., van der Spek, A., Dashti, H. S., Engmann, J., Kocevska, D., Tyrrell, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09576-1 · Cited by 300
Microglial TREM2/DAP12 signaling: a double-edged sword in neural diseases
Konishi, H., & Kiyama, H. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00206 · Cited by 300
Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities
Hemonnot, A.-L., Hua, J., Ulmann, L., & Hirbec, H. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00233 · Cited by 298
Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis
Chen, Y., Strickland, M. R., Soranno, A., & Holtzman, D. M. (2021) · Neuron · doi:10.1016/j.neuron.2020.10.008 · Cited by 298
“In 1993, APOE genotype was found to strongly modulate risk for Alzheimer’s Disease (AD) (Corder et al., 1993; Strittmatter et al., 1993a, 1993b).”
Retinal vascular biomarkers for early detection and monitoring of Alzheimer’s disease
Frost, S., Kanagasingam, Y., Sohrabi, H., Vignarajan, J., Bourgeat, P., Salvado, O., Villemagne, V, Rowe, C. C., Lance Macaulay, S., Szoeke, C., et al. (2013) · Translational Psychiatry · doi:10.1038/tp.2012.150 · Cited by 297
“has been known for some time, the Apolipoprotein E e4 allele (APOE E4).(5) Two biomarkers are showing particular promise, firstly, CSF concentrations of b amyloid (Ab), total t and phosphorylated t peptides,(6,7,11,12) and secondly, brain Ab plaques imaged using Positron Emission Tomography (PET) with C-11 PiB or F18…”
MethodEmerging roles of innate and adaptive immunity in Alzheimer’s disease
Chen, X., & Holtzman, D. M. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.016 · Cited by 297
Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer’s disease
Carrasquillo, M. M., Zou, F., Pankratz, V. S., Wilcox, S. L., Ma, L., Walker, L. P., Younkin, S. G., Younkin, C. S., Younkin, L. H., Bisceglio, G. D., et al. (2009) · Nature Genetics · doi:10.1038/ng.305 · Cited by 296
“Multiple rare mutations in the genes encoding the amyloid β protein precursor, presenilin 1 and presenilin 2 cause an early-onset familial form of Alzheimer's disease with autosomal dominant inheritance, but the only well established susceptibility allele for LOAD is the APOE e4 allel”
Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease
Mormino, E. C., Betensky, R. A., Hedden, T., Schultz, A. P., Ward, A., Huijbers, W., Rentz, D. M., Johnson, K. A., Sperling, R. A., & For the Alzheimer's Disease Neuroimaging Initiative, T. A. I. B. A. L. F. S. O. A. (2014) · Neurology · doi:10.1212/wnl.0000000000000431 · Cited by 293
“A major risk factor for AD is the presence of the APOE e4 allele, which is associated with a decade or more decrease in AD symptom onset.(6) Although APOE e4 influences AD risk through increased Ab accumulation,(7,8) it is also possible that APOE e4 additionally has an independent contribution, or interacts with Ab, t…”
BackgroundTraumatic brain injury and time to onset of Alzheimer’s disease: a population-based study
Nemetz, P. N., Leibson, C., Naessens, J. M., Beard, M., Kokmen, E., Annegers, J. F., & Kurland, L. T. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009724 · Cited by 295
“involved in the transport of cholesterol, a vital component in cell structure and repair (51-55), increases markedly after injury and that the apolipoprotein E *e4 allele, a recognized independent risk factor for Alzheimer's disease, binds closely to the P-amyloid type 4 peptide (54, 56-62).”
BackgroundThe Number of Trait Loci in Late-Onset Alzheimer Disease
Daw, E. W., Payami, H., Nemens, E. J., Nochlin, D., Bird, T. D., Schellenberg, G. D., & Wijsman, E. M. (2000) · The American Journal of Human Genetics · doi:10.1086/302710 · Cited by 295
“The 4 allele has been associated with high risk for AD, relative to the 3 allele, in a large number of studies (e.g., Corder et al. 1993; Jarvik et al. 1995; Levy-Lahad et al. 1998), whereas a smaller number of studies have reported evidence indicating that the less-common 2 allele may have a…”
BackgroundResultInfluentialMetabolomics: A Global Biochemical Approach to the Study of Central Nervous System Diseases
Kaddurah-Daouk, R., & Krishnan, K. R. R. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.174 · Cited by 293
Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide
Hashimoto, T., Serrano-Pozo, A., Hori, Y., Adams, K. W., Takeda, S., Banerji, A. O., Mitani, A., Joyner, D., Thyssen, D. H., Bacskai, B. J., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1542-12.2012 · Cited by 294
Fiore, F., Zambrano, N., Minopoli, G., Donini, V., Duilio, A., & Russo, T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.52.30853 · Cited by 294
Microglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials
Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., & Lan, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1201982 · Cited by 293
“The discovery of APOE4 as the primary genetic susceptibility gene for AD has raised the possibility that lipid transport, including cholesterol and triglyceride metabolism, might be implicated in the disease mechanism (Corder et al., 1993).”
BackgroundNeuroprotective Actions of Dietary Choline
Blusztajn, J., Slack, B., & Mellott, T. (2017) · Nutrients · doi:10.3390/nu9080815 · Cited by 293
Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease
TWAMLEY, E. W., ROPACKI, S. A. L., & BONDI, M. W. (2006) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617706060863 · Cited by 273
“Early studies recruited individuals at risk for AD due to family history (e.g., Hom et al., 1994), whereas more recent studies have focused on older adults with genetic susceptibilities such as the presence of an apolipoprotein E (APOE) ε4 allele (Corder et al., 1993).”
InfluentialClearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L., Daley, D., Black, K. L., & Koronyo-Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 275
“Carriers of a single, and moreover, carriers of double APOE4 alleles have a significantly increased risk of developing AD [51, 151].”
BackgroundAlzheimer's disease in Down syndrome: Neurobiology and risk
Zigman, W. B., & Lott, I. T. (2007) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20163 · Cited by 278
Fagan, A. M., Watson, M., Parsadanian, M., Bales, K. R., Paul, S. M., & Holtzman, D. M. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0483 · Cited by 290
“ApoE4 is associated with an earlier age of onset of AD (Corder et al., 1993) and an increased amyloid plaque burden in those who die with the disease (Rebeck et al., 1993; Schmechel et al., 1993).”
BackgroundGreater cognitive deterioration in women than men with Alzheimer's disease: A meta analysis
Irvine, K., Laws, K. R., Gale, T. M., & Kondel, T. K. (2012) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2012.712676 · Cited by 290
“Another possible explanation for the sex differences in AD patients relates to the apolipoprotein E (APOE) ϵ 4 allele, which is an established genetic risk factor for AD ( Corder et al, 1993 ).”
BackgroundPlasma Total Cholesterol Level as a Risk Factor for Alzheimer Disease: The Framingham Study
Tan, Z. S., Seshadri, S., Beiser, A., Wilson, P. W. F., Kiel, D. P., Tocco, M., D'Agostino, R. B., & Wolf, P. A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1053 · Cited by 280
“T HE APOLIPOPROTEIN E (APOE) 4 allele is a cholesterol transport protein that is a well-established risk factor for late-onset Alzheimer disease (AD).(1) The presence of an APOE 4 allele increases the lifetime risk for development of AD and is also associated with an earlier age of onset.”
BackgroundLi, G., Bien-Ly, N., Andrews-Zwilling, Y., Xu, Q., Bernardo, A., Ring, K., Halabisky, B., Deng, C., Mahley, R. W., & Huang, Y. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.10.015 · Cited by 288
“ApoE4, the major known genetic risk factor for Alzheimer’s disease (AD), is associated with an earlier onset of AD in a gene dose-dependent manner (Corder et al., 1993; Saunders et al., 1993).”
BackgroundChen, J.-H., Lin, K.-P., & Chen, Y.-C. (2009) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(09)60402-2 · Cited by 288
Biological metals and Alzheimer's disease: Implications for therapeutics and diagnostics
Duce, J. A., & Bush, A. I. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.04.003 · Cited by 283
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- University of California, Los Angeles (US)
- Massachusetts General Hospital (US)
- Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710.
- Venue
- Science
- Published
- 1993-08-13
- Volume
- 261
- Issue
- 5123
- Pages
- 921-923
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2036362108
- Cited by
- 9,429
- References
- 16
- Citations by year
- 2026: 289 · 2025: 380 · 2024: 355 · 2023: 328 · 2022: 356 · 2021: 378 · 2020: 396 · 2019: 358 · 2018: 341 · 2017: 343 · 2016: 345 · 2015: 303 · 2014: 343 · 2013: 335 · 2012: 333
- FWCI
- 135.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, gene dosage, Alzheimer's disease, genetic risk, homozygosity, age of onset, genetic association
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Homozygote, Humans, Male, Risk Factors, Linkage Disequilibrium, Survival Rate, Amyloid beta-Peptides, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.